Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2022-02-07 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力关于股份回购进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is titled as an announcement regarding the progress of a share repurchase (股份回购进展情况的公告). It details the number of shares repurchased, prices, and total amount spent, referencing previous announcements and regulatory requirements for disclosure. The document length is about 1000 characters, which is relatively short and focused on share buyback progress updates. This matches the description of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares. It is not a full financial report or earnings release, nor is it a regulatory filing or announcement of a report publication. Therefore, the correct classification is POS.
2022-02-07 Chinese
天士力第八届监事会第5次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding the approval of an asset impairment provision related to a subsidiary's R&D project. It includes voting results and references a related announcement published on the stock exchange website. The document is short (659 characters) and serves as an official meeting resolution announcement rather than a full financial report or detailed management discussion. It does not contain financial statements or detailed financial analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous official announcements that do not fit other specific categories.
2022-01-28 Chinese
天士力关于员工持股计划展期的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the extension of the duration of two employee stock ownership plans by the company TianShiLi Pharmaceutical Group Co., Ltd. It details board meetings and approvals related to extending the plans' terms, references to stock purchase details, and independent director opinions on compliance with regulatory guidelines. The document is relatively short (2209 characters) and focuses on corporate governance and employee stock plan updates rather than financial results or detailed reports. It does not contain financial statements or earnings data, nor is it a proxy solicitation or voting result announcement. It is a regulatory announcement about employee stock plans, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Capital/Financing Update or Management Information. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-01-28 Chinese
天士力2021年年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a "2021 Annual Performance Forecast" (年度业绩预告) and provides preliminary estimated financial results for the full year 2021, including net profit attributable to shareholders and explanations of the main reasons for changes in performance. It explicitly states that the data is preliminary, unaudited, and that the final audited annual report will be published later. The document length is short (1537 characters), and it is a forward-looking earnings preview rather than a full financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR), nor is it a report publication announcement (RPA) because it contains substantive financial estimates and explanations. Therefore, the correct classification is Earnings Release (ER). FY 2021
2022-01-28 Chinese
天士力独立董事关于公司第八届董事会第9次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on specific board meeting matters, including employee stock ownership plans and asset impairment provisions. It references compliance with laws and regulations and provides an independent opinion rather than financial data or full report content. The document is short (657 characters) and does not contain financial statements or detailed financial analysis. It is not an annual report, audit report, or earnings release. It is related to board meeting matters but specifically an independent opinion, which is a type of board/management information. Therefore, the best fitting category is Board/Management Information (MANG).
2022-01-28 Chinese
天士力第八届董事会第9次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of the company, including votes on employee stock plan extensions and asset impairment provisions. It includes voting results and references to other announcements for detailed content. The document is short (935 characters) and serves as a public notice of board decisions rather than a full report or detailed financial statement. It does not contain financial data or detailed management discussion, nor is it a certification or regulatory compliance filing. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2022-01-28 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.